Onco Actu du 22 septembre 2015

	1. Biologie
Grants to help identify variants in the genome’s regulatory regions that affect disease risk [NIH] Six new grants from the National Institutes of Health will support researchers to develop new computational approaches for searching among millions of genomic variants to find those that make a difference in disease susceptibility or in other traits.
	3.1 Tabac
U.S. Preventive Services Task Force Recommends That Clinicians Ask All Adults About Tobacco Use and Offer Ways to Quit [USPSTF] Evidence shows that behavioral therapies and medications are effective for smoking cessation.
Jury still out on e-cigarettes as cessation aid, U.S. doctors say [Reuters] The conclusion, issued by the U.S. Preventive Services Task Force (USPSTF) today as a part of updated recommendations on smoking cessation, adds to an emerging consensus in the medical community that e-cigarettes come with too many unknowns for them to be recommended to current smokers looking to kick the habit.
	4.12 Biopsies liquides
Scientists Identify DNA Alterations as Among Earliest to Occur in Lung Cancer Development [Johns Hopkins] “This study takes detection to a whole new level in terms of size of the lesion,” says David Sidransky, M.D., professor of oncology and pathology at the Johns Hopkins University School of Medicine and the director of head and neck cancer research at Johns Hopkins. “I’m not aware that circulating DNA from precancerous lesions this small has ever been identified before.”
	5. Traitements
Combination therapy could fight pancreatic cancer, say Stanford researchers [Scope Blog] Although much more research needs to be done, the investigators are hopeful that, since vorinostat has already been approved by the Food and Drug Administration, it could be possible to move more quickly than normal to test this drug combination in patients with pancreatic cancer. They also found intriguing hints that the duo may be effective in other types of Ras-driven cancers, including lung adenocarcinoma.
Targeting DNA [MIT News] MIT biological engineers have developed a modular system of proteins that can detect a particular DNA sequence in a cell and then trigger a specific response, such as cell death.
Our milestones: the birth of a new prostate cancer drug [Cancer Research UK] In the latest in Our milestones, we look back to the 1990s, and to our ‘first-in-man’ trial of prostate cancer drug abiraterone – a vital step in the drug’s development that set the scene for its progression through to routine use on the NHS.
Study: Brentuximab Vedotin Effective, Safe in Elderly Hodgkin Lymphoma Patients Who Cannot Tolerate Standard Chemotherapy [ASH] First trial to evaluate brentuximab vedotin as a front-line treatment.
	5.2 Pharma
With $75M, Deciphera Fuels Push For Cancer Drugs---And a Future IPO [Xconomy] Taylor contends this approach is distinctive in that it should lead to more durable, longer-lasting kinase-inhibiting drugs, and be applicable to a broader range of cancers. Deciphera’s drugs are designed to lock a mutated kinase in its inactive shape so it can’t begin firing bad signals—say, for a cell to grow uncontrollably.
Houston’s Fannin Forms Company to Fight Inflammation-Induced Cancers [Xconomy] ACF Pharmaceuticals, which will be based in Houston, will work closely with MD Anderson and Ann Arbor, MI-based Cayman Chemical on discovering and developing small molecule inhibitor to treat inflammation-induced cancers such as melanoma, as well as colon and pancreatic cancers.
AstraZeneca taps crowd sourcing to find cancer drug cocktails [Reuters] The company said on Tuesday its decision to release preclinical data from more than 50 of its medicines was unprecedented in scale and would help accelerate the hunt for synergistic tumor-fighting drug combinations.
	5.2.3 Pharma - économie
Thanks, Turing. Your 5000% price hike puts pharma in the election hot seat [FiercePharma] The last thing pharma needs right now is a scandalous price hike to turn up the heat even further. But that's just what Turing Pharma and its CEO, Martin Shkreli, have on offer.
What to Do About Turing (And the Others) [In the Pipeline] Martin Shkreli is going around saying that Turing is just a tiny little company, raising prices on a tiny little drug – and although that’s probably true, it doesn’t matter. This sort of thing could be a catalyst for far bigger changes, and many of those would be very unpleasant for the rest of the industry.
	5.3 Traitements - FDA, EMA,...
CHMP Chair re-elected [EMA] Looking to the future, Dr Salmonson sees three key priorities for the CHMP...
‘Breakthrough’ drug may not mean what you think [Reuters] “To protect patients from spurious hopes for miracle cures, Congress and the FDA should abandon the adoption of terminology like breakthrough and focus on strengthening the evidentiary requirements for meaningful clinical data to ensure the promise of new drugs and devices.”
	5.4 Traitements - Economie
Democrat Clinton to unveil plan to fight drug 'price gouging' [Reuters] Clinton's comments on Monday were her first about how to tackle high drug prices, but she has talked about the problems facing consumers before.
Cancer Drugs Fund Removes Funding for Two Life-Prolonging Myeloma Drugs [Laboratory News] As part of a second reassessment of the Cancer Drugs Fund, NHS England has announced that Imnovid® (pomalidomide) and Revlimid® (lenalidomide) at first relapse for the rare bone marrow cancer myeloma, will be removed from the list.
On the Agenda: Prescription Drug Costs Are Rising as a Campaign Issue [NY Times] Americans have long paid the highest prices for drugs. Because the United States gives drug makers long periods of patent exclusivity and lets a multitude of insurers each negotiate with drugmakers on price, drug spending here is, on a per capita average, roughly double the amount spent in many developed countries.
	5.5.2 ASCO (sein)
2015 Symposium Highlights Notable Advances in Breast Cancer Research [ASCO] This will be the final year for the Breast Cancer Symposium, held annually since 2007.
	5.6 ESMO
Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types [Merck] Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy.
	6. Lutte contre les cancers
Five Ways Individualized Medicine is Impacting Health Care [Mayo Clinic] How is individualized medicine working? Let us count the ways. That’s just what Mayo Clinic Vice President Gianrico Farrugia, M.D., did this morning in his opening keynote at the 4th annual Individualizing Medicine Conference.
	6.8 Communication
Stand Up To Cancer hosts first of its kind YouTube party [Cancer Research UK] ‘YouTube Stands Up To Cancer’ will harness the power and global reach of YouTube, with vlogging superstars joined by well known faces from film, television and music to do what they do best – live on YouTube.